Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMAGINE: Imaging Biomarkers for Brolucizumab in wAMD
NCT04774926Phase 4Completed
- Sponsor
- Novartis
- Start
- Oct 2021
- Primary completion
- Oct 2023
- Modality
- scFv Fragments, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of brolucizumab in neovascular age-related macular degeneration (NVAMD), sponsored by Novartis. Started Oct 2021; status: completed.
02
Drugs
brolucizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT04774926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04774926.